-
United Imaging Healthcare Acquires Stake in Apactron for High-End Particle Therapy Technology
•
Shanghai-based United Imaging Healthcare (UIH, SHA: 688271) has announced an investment of RMB 45 million (USD 6.3 million) to acquire a 4.7% stake in Shanghai Apactron Particle Equipment Co., Ltd., a company specializing in high-end particle therapy technology. This strategic deal is aimed at leveraging Apactron’s expertise in proton therapy…
-
Sequanta Technologies Partners with DarkJade Sciences to Establish Organoid Bank and Glioma Project
•
Sequanta Technologies, a leading multi-omics research and clinical service provider based in Shanghai, has announced a partnership with DarkJade Sciences, a renowned organoid specialist based in Beijing. The collaboration aims to leverage the respective strengths of both companies to establish an organoid bank, with the first project focusing on glioma…
-
Insilico Medicine Partners with ShanghaiTech University for Tumor Drug R&D Advancement
•
China-based AI-powered drug discovery firm Insilico Medicine has struck a partnership with ShanghaiTech University’s iHuman institute to bolster the research and development of tumor drugs with novel targets. This collaboration aims to leverage Insilico’s generative AI platform and ShanghaiTech’s expertise in structural biology to advance drug discovery. Leveraging AI for…
-
WinHealth Pharma Receives NMPA Approval for Glycerol Phenylbutyrate for Urea Cycle Disorders
•
China-based Hong Kong WinHealth Pharma Group Ltd has announced receiving market approval from the National Medical Products Administration (NMPA) for its glycerol phenylbutyrate, a drug used as a long-term treatment for patients with urea cycle disorders (UCDs). This approval specifically targets patients who cannot achieve disease control through protein intake…
-
Nanjing Leads Biolabs Receives FDA IND Approval for LBL-033 Phase I/II Clinical Trial
•
China-based Nanjing Leads Biolabs Co., Ltd has revealed that it has received Investigational New Drug (IND) approval from the US Food and Drug Administration (FDA) to initiate a Phase I/II clinical trial for its pipeline candidate, LBL-033. This anti-MUC16/CD3 bispecific antibody (BsAb) is set to be investigated as a potential…
-
AstraZeneca Weighs Spinning Off China Business to Shield Against Geopolitical Tensions
•
According to a report from the UK newspaper The Financial Times (FT), AstraZeneca (AZ, NASDAQ: AZN) has drafted plans to spin off its China business as a separate entity. Citing “three people familiar with the talks,” the UK-based pharmaceutical giant is said to have begun discussing the idea with bankers…
-
TG ImmunoPharma Receives FDA Approval for Phase I Clinical Study of TGI-6 Bispecific Antibody
•
China-based TG ImmunoPharma Co., Ltd has announced that it has received approval from the US Food and Drug Administration (FDA) to conduct a Phase I clinical study for its bispecific antibody (BsAb), TGI-6. This development marks a significant step forward in the company’s efforts to bring innovative immunotherapies to patients…
-
IASO Bio Receives FDA IND Approval for IASO-782 for Autoimmune Disorders
•
China-based IASO Bio has announced that the US Food and Drug Administration (FDA) has approved an Investigational New Drug (IND) filing for its pipeline candidate, IASO-782. This injectable drug candidate will be assessed in US clinical trials for the treatment of various autoimmune hematological disorders, including primary immune thrombocytopenia (ITP)…
-
Adicon Holdings Ltd IPO: A Strategic Move for Growth in Diagnostics
•
Adicon Holdings Ltd (HKG: 9860), a China-based independent clinic laboratory (ICL) service provider, has successfully completed its initial public offering (IPO) of 33.2 million shares on the Hong Kong Stock Exchange. The shares were priced at HKD 12.32 (USD 1.58) each, with net proceeds expected to reach HKD 83.9 million…
-
Acotec Scientific Holdings and Boston Scientific Group plc Sign MOU to Broaden Collaboration
•
China-based Acotec Scientific Holdings Ltd (HKG: 6669) has announced a memorandum of understanding (MoU) with US firm Boston Scientific Group plc (BSG, NYSE: BSX), signaling their intention to explore collaboration in multiple fields, including research and development (R&D), manufacturing, and marketing and sales. Financial details of the agreement were not…
-
Aosaikang Pharmaceutical’s ASKB589 Shows Promising Results in Solid Tumor Treatment Study
•
Beijing Aosaikang Pharmaceutical Co., Ltd (SHE: 002755) has revealed the latest results from a Phase I/II study for its Category 1 biologic product candidate ASKB589, which is being assessed as a treatment for solid tumors. The findings were presented at the 15th International Gastric Cancer Association (IGCA) meeting, highlighting the…
-
Jiangsu Hengrui Medicine Cancels Licensing Agreement with Mabworks Citing Market Changes
•
China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276) has announced its decision to cancel a licensing agreement with compatriot firm Mabworks, along with a related equity investment deal, due to changes in the market landscape. This move signifies that Hengrui Pharmaceuticals will no longer hold exclusive commercialization rights to Mabworks’…
-
Roche’s Evrysdi Receives NMPA Approval for Wider SMA Patient Age Range
•
Swiss pharmaceutical giant Roche (SWX: ROG) has announced that its blockbuster nervous system drug Evrysdi (risdiplam) has received market approval from the National Medical Products Administration (NMPA) to treat spinal muscular atrophy (SMA) in patients aged 16 days and above. This marks an expansion of the drug’s indication in China,…
-
MicuRx Pharmaceuticals’ MRX-4/Contezolid Combo Receives Clinical Trial Approvals for Diabetic Foot Infection
•
Sino-US firm MicuRx Pharmaceuticals Inc. (SHA: 688373) has announced receiving clinical trial approvals for its novel anti-microbial agent MRX-4, combined with contezolid (MRX-I), as a sequential treatment for diabetic foot infection in Israel, Bulgaria, Slovakia, Croatia, Poland, and Brazil. In-House Developed Oxazolidinone AntibioticsBoth MRX-4 and contezolid are in-house developed new-generation…
-
AstraZeneca Enters Three-Year Collaboration with Cholesgen for Metabolic Disease Therapies
•
UK-based pharmaceutical giant AstraZeneca (AZ, NASDAQ: AZN) has signed a three-year collaboration agreement with China-based Cholesgen (Shanghai) Co., Ltd. The partnership focuses on the research and development of new therapies for hypercholesterolemia and other metabolic diseases. The collaboration aims to validate genetic drug targets and advance therapeutic molecules into clinical…
-
BeiGene to Showcase Brukinsa Data at ICML, Highlighting Efficacy in Relapsed Follicular Lymphoma
•
China-based biopharmaceutical company BeiGene (NASDAQ: BGNE, HKG: 6160, SHA: 688235) has announced that it will present data on its Bruton’s tyrosine kinase inhibitor (BTKi) Brukinsa (zanubrutinib) at the 17th International Conference on Malignant Lymphoma (ICML). The data highlights the potential of Brukinsa in combination with obinutuzumab for the treatment of…
-
Fosun Pharma Initiates Phase II Study of HLX26 and Serplulimab Combo for Metastatic CRC
•
Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) has announced the initiation of a Phase II clinical study in China for HLX26, an in-house developed lymphocyte activation gene 3 (LAG-3, aka CD233) inhibitor, in combination with its programmed-death 1 (PD-1) inhibitor HaiSiZhuang (serplulimab) for the treatment of metastatic…
-
Takeda and HutchMed’s Elunate Study Results Published in The Lancet
•
Takeda (TYO: 4502) and HutchMed (China) Ltd (HKG: 0013, NASDAQ: HCM) have announced that the results of the Phase III FRESCO-2 study for Elunate (fruquintinib) in previously treated metastatic colorectal cancer (mCRC) have been published in The Lancet journal. The global Phase III study, conducted across the US, Europe, Japan,…
-
CStone’s Sugemalimab Shows Promising Survival Rates in Stage IV NSCLC Treatment
•
China-based CStone Pharmaceuticals (HKG: 2616) has announced that the prestigious journal Nature Cancer has published the overall survival (OS) interim analysis from the registrational clinical study GEMSTONE-302. The study evaluates the programmed death-ligand 1 (PD-L1) inhibitor sugemalimab as a first-line treatment for stage IV non-small cell lung cancer (NSCLC). GEMSTONE-302…
-
Gates Foundation Renews Partnership with Beijing and Tsinghua to Boost Infectious Disease Research
•
The Bill & Melinda Gates Foundation has announced the renewal of its collaboration with the Beijing Municipal Government and Tsinghua University to support the Beijing-based Global Health Drug Discovery Institute (GHDDI) in its quest to develop therapies for infectious diseases. This renewed commitment will see the Gates Foundation contribute USD…
